On April 10, 2018, e-VIS received approval from EMVO (European Medicines Verification Organization) and was connected to the production environment in the EMVS. This is an important milestone for Sweden to be able to support the EU Directive 2011/62/EU on Falsified Medicines. Sweden together with Slovenia, Ireland and Denmark are among the first countries to receive production approval.
e-VIS could not have reached this milestone without active support from the many stakeholders involved and without close and good cooperation with the other countries with the same blueprint provider
Deployment of a new pharmaceutical services system requires changes in many different systems and methods. Below are answers to some of the questions that e-VIS and the implementation project have received. (NTIN to GTIN, Costs, Tests, Contracts, etc.).